Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2020-12-01 Investor Presentation
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Investor Presentation Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces Ipsen's strategic priorities and mid-term financial outlook during a "virtual Capital Markets Day." It provides key financial guidance (Net Sales CAGR 2020-2024) and discusses capital allocation, but it is not the full, comprehensive annual report (10-K) or a detailed interim report (IR). It functions as an initial announcement of strategic direction and financial expectations, which aligns best with an Earnings Release (ER) or a presentation/update document. Since it details strategy, outlook, and financial targets following a specific event (Capital Markets Day), it is most closely related to an Investor Presentation (IP) or an Earnings Release (ER). Given the context of presenting strategic updates and financial outlook, 'Investor Presentation' (IP) is a strong fit, as Capital Markets Days often involve detailed presentations. However, since it is formatted as a press release announcing the event and its key takeaways, and often these strategic updates are released concurrently with or immediately following an earnings period, 'ER' (Earnings Release) or 'IP' (Investor Presentation) are the closest. Because it focuses heavily on strategy, R&D investment, and a multi-year outlook rather than just quarterly results, 'IP' is slightly more appropriate than a standard 'ER' which usually focuses on the immediate past period's results. However, the content is a high-level summary of strategic direction and financial targets, which is often the core of an Investor Presentation (IP). I will classify it as an Investor Presentation (IP) due to the focus on strategy, R&D, and mid-term outlook presented during a Capital Markets Day.
2020-12-01 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces Ipsen's "nouvelles priorités stratégiques et ses objectifs financiers à moyen terme" (new strategic priorities and medium-term financial objectives). It details strategic focus areas (Oncology, Rare Diseases, Neuroscience), R&D investment plans, efficiency gains, and specific medium-term financial targets (2020-2024 revenue CAGR, R&D investment capacity). This content strongly aligns with an Investor Presentation (IP) or a high-level strategic update often presented during an Investor/Capital Markets Day. Since it outlines strategy, financial targets, and is presented as a formal announcement detailing future plans rather than just summarizing past earnings (ER) or being a full annual report (10-K), 'Investor Presentation' (IP) is the most appropriate classification. It is not a short announcement linking to a report (RPA/RNS), but the substance of the presentation itself.
2020-12-01 French
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a press release from Ipsen, dated November 30, 2020, announcing that the FDA granted 'Fast Track' designation for ONIVYDE® in treating Small Cell Lung Cancer (SCLC). It details the drug's current approvals, ongoing clinical trials (Phase III RESILIENT), the implications of the Fast Track designation, and includes Important Safety Information (Boxed Warnings, Contraindications, Adverse Reactions) for ONIVYDE®. This content structure—a news announcement about a regulatory event (Fast Track designation) combined with detailed safety and prescribing information—is characteristic of a press release announcing significant clinical or regulatory progress, often accompanying or preceding a formal filing. Since it is a formal announcement of a regulatory/clinical development rather than a comprehensive annual report (10-K), an interim report (IR), or a transcript (CT), it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a quarterly period, but the focus here is purely regulatory/clinical news. Given the specific nature of the announcement (FDA designation) and the inclusion of detailed safety information typical of regulatory communications, RNS (Regulatory Filings) is the most appropriate general category, as it is a formal communication to the market about a regulatory event that doesn't fit the other specific categories like ER or MDA. However, looking closely at the definitions, this is a press release announcing a regulatory milestone (Fast Track designation) and providing detailed drug information. This type of announcement is often categorized as a general Regulatory Filing (RNS) or sometimes an Earnings Release (ER) if it's part of a quarterly update cycle. Since it is not a comprehensive financial report (10-K, IR) or a management discussion (MDA), RNS serves as the best fit for a specific regulatory update announcement that isn't a dividend or management change.
2020-11-30 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated November 30, 2020, announcing that Ipsen received FDA Fast Track designation for a drug (ONIVYDE®) for SCLC treatment. It details the drug's current indication, ongoing clinical trials, safety information (including Boxed Warnings), and company background. This content structure—a news announcement about a regulatory event (Fast Track designation) and associated clinical/safety data—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/pipeline news. Since it is not a full quarterly/annual report (10-K or IR), nor a transcript (CT), nor a specific shareholder/governance document, and it focuses on key operational/pipeline news, it best fits the 'Earnings Release' category, which often encompasses major corporate announcements outside of routine financial reporting periods, or the general 'Regulatory Filings' (RNS) if the focus is purely on the FDA designation. Given the detailed nature of the announcement, including safety information and trial updates, it functions as a major corporate update, similar to what might accompany an earnings announcement, but since it is not explicitly labeled as an 'Earnings Release' and is focused on a regulatory milestone, the most appropriate general category for significant, non-standard corporate news that isn't a full report is often RNS, or ER if it's a standalone announcement of results/developments. However, looking at the definitions, this is a specific announcement of a regulatory event (Fast Track designation) and associated product information. It is not a comprehensive financial report (10-K, IR) or a management discussion (MDA). It is a press release announcing a significant development. In many databases, such press releases announcing regulatory milestones are classified under a general news/regulatory category. Given the options, 'Regulatory Filings' (RNS) is the best fit for a press release detailing an FDA action, as it is a regulatory event announcement that doesn't fit the other specific report types. It is not short enough to be a simple RPA.
2020-11-30 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Share Issue/Capital Change Classification · 1% confidence The document explicitly states it provides 'Monthly information relative to the total number of voting rights and shares composing the share capital' and references French regulatory articles (AMF). This type of regular disclosure regarding the total number of shares and voting rights, often published monthly, is a specific regulatory filing related to share capital structure and ownership transparency. While it touches upon voting rights, it is not the results of a vote (DVA) or a general capital change announcement (SHA/POS). It is a routine disclosure of the capital base. Given the options, this specific monthly disclosure about the total number of shares and voting rights most closely aligns with a general regulatory filing or a specific disclosure related to capital structure that doesn't fit the other precise categories. Since it is a mandatory, periodic disclosure about the share capital base, it is best classified as a Regulatory Filing (RNS) as it is a specific regulatory disclosure that doesn't match the other defined categories like DIV, SHA, or DVA.
2020-11-10 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de Commerce and AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of a specific date (October 31, 2020). This structure is characteristic of a mandatory periodic disclosure regarding the share capital structure and voting rights, which aligns best with the general regulatory filing category, as there is no specific code for 'Monthly Voting Rights Disclosure'. Given the options, 'RNS' (Regulatory Filings) is the most appropriate fallback for a mandatory, periodic regulatory disclosure that doesn't fit the specific financial report types (10-K, IR, ER, etc.). The document length is short (1480 chars), but it is the report itself, not an announcement of a report, so RPA is not applicable.
2020-11-10 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.